OncoSil Medical Ltd (AU:OSL) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OncoSil Medical Limited has achieved a significant milestone with the German Federal Joint Committee’s approval for a trial of its pancreatic cancer treatment, which will be conditionally reimbursed. The company also received draft approval for its Medical Device Regulation, removing post-market restrictions and reducing costs, thus enhancing market access in the EU and UK. Furthermore, OncoSil is actively engaging with the FDA to expedite approval for its device in treating distal cholangiocarcinoma in the U.S.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.